Ipsen S.A. (OTCMKTS:IPSEY – Get Rating) has received an average recommendation of “Hold” from the eleven research firms that are covering the company, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, six have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $100.00.
Several equities analysts recently weighed in on the stock. Societe Generale raised shares of Ipsen from a “hold” rating to a “buy” rating in a research note on Thursday, January 6th. Zacks Investment Research cut shares of Ipsen from a “buy” rating to a “hold” rating in a research note on Wednesday, December 29th. JPMorgan Chase & Co. cut shares of Ipsen from an “overweight” rating to a “neutral” rating in a research note on Tuesday, January 4th. Barclays lifted their price objective on shares of Ipsen from €88.00 ($95.65) to €95.00 ($103.26) and gave the stock an “underweight” rating in a research note on Thursday. Finally, UBS Group raised shares of Ipsen from a “neutral” rating to a “buy” rating in a research note on Tuesday, January 11th.
IPSEY opened at $30.41 on Wednesday. The company has a fifty day moving average of $29.35 and a 200 day moving average of $26.26. Ipsen has a fifty-two week low of $21.71 and a fifty-two week high of $32.51.
Ipsen SA operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, and chronic renal failure, as well as GH deficiency in adults; and Increlex for growth failure in children and adolescents.
- Get a free copy of the StockNews.com research report on Ipsen (IPSEY)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
Receive News & Ratings for Ipsen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ipsen and related companies with MarketBeat.com's FREE daily email newsletter.